Ted Buchan & Co Makes New Investment in Pfizer Inc. (NYSE:PFE)

Ted Buchan & Co bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 26,395 shares of the biopharmaceutical company's stock, valued at approximately $700,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer in the 4th quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer during the fourth quarter valued at $28,000. Noble Wealth Management PBC acquired a new position in shares of Pfizer during the fourth quarter worth $31,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer in the fourth quarter worth $32,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent research reports. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Bank of America reissued a "neutral" rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Truist Financial dropped their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

Remove Ads

Pfizer Stock Down 5.4 %

Pfizer stock traded down $1.30 during midday trading on Friday, reaching $22.99. The stock had a trading volume of 79,829,399 shares, compared to its average volume of 39,460,357. The company has a fifty day moving average price of $25.87 and a two-hundred day moving average price of $26.72. Pfizer Inc. has a 12 month low of $22.95 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $130.39 billion, a P/E ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the previous year, the company posted $0.10 earnings per share. The company's quarterly revenue was up 24.7% on a year-over-year basis. As a group, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.